Compare Allstate Corp (ALL) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allstate Corp vs ARK Genomic Revolution ETF — how do they compare? Allstate Corp trades at $252.97 (market cap $64.77B), while ARK Genomic Revolution ETF trades at $40.95. The key difference: Allstate Corp pays a 1.72% dividend while ARK Genomic Revolution ETF pays none, and Allstate Corp is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ALL | ARKG | |
|---|---|---|
Market Cap | $64.77B | — |
Sector | Financials | Sector/Thematic |
52-Week High | $251.61 | $43.57 |
52-Week Low | $190.00 | $23.09 |
Enterprise Value | $73.56B | — |
Dividend Yield | 1.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
